2012
London, UK, 11 December 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces the appointment of Richard Wohanka as a non-executive director of the Board, effective from 1...
London, UK, 20 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, notes the announcement by Janssen-Cilag International NV (Janssen) that the Committee for Medical Products for...
London, UK, 19 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces that full data from VANISH-1 and VANISH-2, the two US pivotal Phase III trials of polidocanol...
London, UK, 08 November 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim results for the six months ended 30 September 2012. Click here to down load the PDF
London, UK, 03 October 2012 BTG plc (LSE: BTG), the specialist healthcare company, provides the following update for the six months ended 30 September 2012 ahead of the planned publication of its...
London, UK, 17 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Andy Burrows, Director of Investor Relations will be presenting an overview of the company...
London, UK, 10 September 2012 BTG plc (LSE: BTG), the specialist healthcare company today announces that Louise Makin, CEO will be presenting an overview of the company and its strategic...
West Conshohocken, PA, 05 September 2012 New Technology Add-on Payment provides up to 50% of the cost of Voraxaze®prescribed in the inpatient setting BTG International Inc., the specialist...
London, UK, 08 August 2012 BTG plc (LSE: BTG), announces top-line data from a global double-blind Phase IIb study comparing the efficacy and safety of two doses of AZD9773 (CytoFab™) with...
London, UK, 17 July 2012 BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim management statement for the period from 1 April 2012 to 16 July 2012. Trading within...